VBI Vaccines (VBIV)

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Company profile

Ticker

VBIV

Exchange

NASDAQ

Website

www.vbivaccines.com

CEO

Jeffrey R. Baxter

Incorporated

British Columbia, Canada

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.

SEC CIK

0000764195

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

VBI Vaccines (Delaware) Inc. • SciVac Ltd. • Variation Biotechnologies (US), Inc. • Variation Biotechnologies Inc. • SciVac Hong Kong Limited ...

VBIV stock data

1M 1Y 5Y

News

From Benzinga Pro

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise

23 Jun 22

Here's a roundup of top developments in the biotech space over the last 24 hours:

22 Stocks Moving in Thursday's Pre-Market Session

23 Jun 22

Gainers WISeKey International Holding AG (NASDAQ: WKEY) rose 74.4% to $2.32 in pre-market trading. WISeKey International recently issued 2022 first-half revenue guidance for its IoT segment.

Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jun. 22, 2022: DIS, THO, CEI, FERG, VBIV

22 Jun 22

Today's 5 Stock Ideas: Disney (DIS) - ARK Invest's Cathie Wood sold nearly all of her position in Disney this week, about $7 million worth. Thor Industries (THO) - A peer play following earnings out

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

22 Jun 22

VBI Vaccines Granted Orphan Drug Designation For Treatment Of Glioblastoma

17 Jun 22

Press releases

From Benzinga Pro

VBI Vaccines Announces Results of Annual General Meeting

22 Jun 22

VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

22 Jun 22

- FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients - Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in

VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting

6 Jun 22

- Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 - One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

26 May 22

VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update

9 May 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

9 May 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart VBIV financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	101.34M	101.34M	101.34M	101.34M	101.34M	101.34M
Cash burn (monthly)	6.79M	574.08K	7.08M	6.29M	6.64M	4.43M
Cash used (since last report)	19.47M	1.65M	20.33M	18.04M	19.06M	12.72M
Cash remaining	81.87M	99.69M	81.01M	83.3M	82.28M	88.62M
Runway (months of cash)	12.1	173.7	11.4	13.2	12.4	20.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

VBIV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 22	Anderson David Evander	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.53	400,000	612K	400,000
27 Jan 22	Bain Linda	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.53	75,000	114.75K	75,000
27 Jan 22	Baxter Jeff	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.53	800,000	1.22M	800,000
27 Jan 22	Beattie Nell	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.53	400,000	612K	400,000
27 Jan 22	Damian Braga	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.53	75,000	114.75K	75,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

VBIV institutional ownership history Ownership history

44.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	129	135	-4.4%
Opened positions	15	21	-28.6%
Closed positions	21	11	+90.9%
Increased positions	46	47	-2.1%
Reduced positions	35	39	-10.3%

13F shares	Current	Prev Q	Change
Total value	191.15M	351.73M	-45.7%
Total shares	115.36M	111.33M	+3.6%
Total puts	195.4K	544.7K	-64.1%
Total calls	260.5K	393.9K	-33.9%
Total put/call ratio	0.8	1.4	-45.8%

Largest owners	Shares	Value	Change
Perceptive Advisors	52.34M	$86.88M	0.0%
STT State Street	16.22M	$26.92M	+31.1%
BLK Blackrock	13.22M	$21.95M	-0.4%
Vanguard	5.07M	$8.42M	-0.2%
Geode Capital Management	3.93M	$6.52M	+4.2%
Cambridge Investment Research Advisors	2.19M	$3.64M	+2.0%
NTRS Northern Trust	1.89M	$3.14M	-4.9%
GAM General American Investors	1.88M	$3.12M	0.0%
Charles Schwab Investment Management	1.64M	$2.73M	+2.7%
Rafferty Asset Management	1.09M	$1.82M	+29.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	16.22M	+3.84M	+31.1%
Millennium Management	571.36K	-1.17M	-67.2%
Susquehanna International	414.72K	-829.93K	-66.7%
MS Morgan Stanley	980.66K	+744.05K	+314.5%
Frontier Wealth Management	601.8K	+565.8K	+1571.7%
C Citigroup	176.38K	-475.43K	-72.9%
BAC Bank Of America	809.43K	+380.84K	+88.9%
UBS UBS Group AG - Registered Shares	1.03M	+322.96K	+45.5%
Rafferty Asset Management	1.09M	+248.27K	+29.3%
Group One Trading	98.61K	-245.31K	-71.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Dynavax Technologies • Enanta Pharmaceuticals • Altimmune • Silverback Therapeutics • Hookipa Pharma

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ACIP, acute, Additionally, adjusted, adjustment, adsorbed, adult, ancestral, animal, Area, asymptomatic, bat, begun, benchmarked, bifurcated, bite, brain, Brazil, burden, CDC, cGMP, chemotherapy, childbirth, CHMP, cold, Combo, conclusion, conflict, contemplated, decade, difficult, distant, divergent, drawn, East, EC, ECDRP, EEA, EU, exhibit, field, Floor, formal, geopolitical, Gilbert, Iceland, inclusion, India, inflammation, inhibitor, injury, instrument, interferon, internationally, joined, joint, knowledge, Lambda, Liechtenstein, longer, low, macroeconomic, main, malignant, median, Medicinal, member, mice, Middle, mild, month, mortality, mosquito, move, neurological, newly, North, Norway, nrtl, Omicron, outbreak, overview, passed, pathogenic, PB, pegylated, persistently, PNA, pregnancy, PreHevbri, PreHevbrio, PRNT, Procedure, pseudoparticle, radiation, recommendation, recommended, reimbursed, resection, respiratory, reverse, ROU, Russia, seasoned, sexually, silent, stronger, subvariant, summer, surgical, sustain, Syndrome, therapy, title, today, topline, transcriptase, transmitted, turn, typically, Ukraine, unanimously, unaware, underway, universally, VOC, voted, week, Zika

Removed: abandon, AgreementSM, Application, approve, awarded, BLA, block, BMI, boost, broadly, capacity, certificate, certification, CHO, closed, Coalition, comply, consecutive, consistency, consistent, CONSTANT, deep, demonstrating, diabetic, diminish, directly, distinguished, divided, Epidemic, equipment, exclusively, expression, Fee, GMP, governed, granting, guarantee, hepatocellular, III, immunological, IMoH, indirectly, inhibit, leading, load, LP, mammalian, modernization, modernized, multiplied, obligated, PDUFA, Perceptive, pivotal, practice, Prescription, problem, PROTECT, reactive, recently, receptor, Region, remained, remove, restoration, robust, sensitive, seroprotection, simplify, size, Society, sponsor, SPR, subgroup, submitted, superiority, temporarily, transmissibility, understanding, uniquely, unknown, User, validation, vary, yeast

From filing 10-Q 2022 Q1

Financial reports

View all